Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tryptamine Therapeutics ( (AU:ENP) ) just unveiled an update.
Entropy Neurodynamics Limited has notified the market of the issue of 2 million unquoted options, each exercisable at A$0.08 and expiring on 19 December 2027. The options, which form part of a previously announced transaction and will not be quoted on the ASX, modestly expand the company’s pool of unquoted equity and may provide additional incentive or funding flexibility for the business without immediately diluting existing shareholders in the traded ordinary shares.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited (ASX: ENP) is an Australia-listed company operating in the neurotechnology/biotechnology sector. While this notice provides limited operational detail, the company’s activities are centred on developing neurological solutions, and its securities are traded on the Australian Securities Exchange under the code ENP.
Average Trading Volume: 2,536,966
Technical Sentiment Signal: Sell
Current Market Cap: A$53.11M
See more data about ENP stock on TipRanks’ Stock Analysis page.